ReviewDrugs2021
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.Renal failure · 2024Pooled it
- A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Guideline
- Incidence of hyperkalemia RAASi and SGLT-2i treatment in individuals with diabetic kidney disease: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden.Toxicology reports · 2026Review
- Sodium zirconium cyclosilicate post hospital discharge to prevent hyperkalaemia: phase 4, randomized CONTINUITY trial.Clinical kidney journal · 2026Article
- Development and validation of a machine learning-based risk prediction model for hyperkalemia in patients with chronic kidney disease.Scientific reports · 2026Article
- Impact of Duration of Outpatient Sodium Zirconium Cyclosilicate Therapy on Hyperkalemia-Related Health Care Resource Utilization: A Matched Cohort Analysis.Kidney medicine · 2026Article
- Prevalence of Hyperkalemia in a Contemporary European Cohort According to EKFC eGFR Categories.Diagnostics (Basel, Switzerland) · 2026Article
- Electronic health record dynamic features for in-hospital death among chronic kidney disease patients.Scientific reports · 2026Article
- Study protocol for a prospective, multicenter, single-arm study investigating the impact of the implementation of standardized hyperkalemia management in chronic kidney disease patients.BMC nephrology · 2026Article
- In vivo electrochemical reduction-induced reconfiguration of Prussian blue for metal counterion-free potassium removal in hyperkalemia.Nature communications · 2025Article
- Mechanism of mesenchymal stem cells in treating diabetic kidney disease.Stem cell research & therapy · 2025Review
- Evaluation of the Correlation between Gut Microbiota and Renal Function in Chronic Kidney Disease Patients.Journal of microbiology and biotechnology · 2025Article
- Hyperkalemia and the Risks of Adverse Cardiovascular Outcomes in Patients With Chronic Kidney Disease.Journal of the American Heart Association · 2025Article
- Artificial intelligence in chronic kidney diseases: methodology and potential applications.International urology and nephrology · 2025Review
- Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?Clinical kidney journal · 2024Article
- Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality.JACC. Advances · 2024Article
- Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care.Kidney medicine · 2024Article
- Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models.International journal of molecular sciences · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent therapeutic advances, chronic kidney disease (CKD) is one of the fastest growing global causes of death. This illustrates limitations of current therapeutic approaches and, potentially, unidentified knowledge gaps. For decades, renin-angiotensin-aldosterone system (RAAS) blockers have been the mainstay of therapy for CKD. However, they favor the development of hyperkalemia, which is already common in CKD patients due to the CKD-associated decrease in urinary potassium (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.